RESEARCH TRIANGLE PARK, N.C., June 8, 2011 /PRNewswire/ —
(NASDAQ:
GRFS) – Grifols, a global healthcare company and
biopharmaceutical manufacturer based in Barcelona, Spain, today
announced that it has officially begun to merge its operations with
Talecris Biotherapeutics in order to function as one company,
following its acquisition of Talecris on June 1. Through the
acquisition, Grifols will build upon its 70-year legacy of creating
life-saving medicines and products by incorporating Talecris’
substantial experience and skill in producing plasma protein
therapies.
“The union of our two companies provides an infusion of energy
and talent, and strengthens our commitment to our shared mission of
providing life-saving therapies to patients with rare, chronic
diseases,” said Victor Grifols, President and CEO of Grifols.
“The strength of our combined company is not simply its size;
rather, it is the potential to achieve more for patients in the
future than either company would be able to accomplish on its
own.”
Combining the respective capabilities of the two companies will
allow Grifols to extract more products from each liter of plasma
and thus increase the quantity of products and choices available to
patients. The company’s expanded global footprint will also improve
patient access to critical-care protein therapies that are not
widely available in many countries.
“The Grifols family has been a leader in producing safe,
effective plasma therapies,” said John Walsh, president and CEO of
the Alpha-1 Foundation. “Under Victor Grifols’ leadership we expect
that family culture to expand in the United States. The Alpha-1
community has always been a family, and we look forward to a
complementary blending of two family traditions.”
“Grifols and Talecris have each made significant contributions
to the treatment of people with primary immune def
‘/>”/>
